Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.

PHASE4CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 16, 2018

Primary Completion Date

September 19, 2020

Study Completion Date

September 19, 2020

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

Insulin Degludec

Subjects will use Insulin Degludec (Tresiba) with TRESIBA® FLEXTOUCH® pens as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.

DRUG

Insulin Glargine

Subjects will use Insulin Glargine (Lantus) with LANTUS® SOLOSTAR® INSULIN PEN as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.

DEVICE

TRESIBA® FLEXTOUCH®

Subjects will use Tresiba FlexTouch pens when using Tresiba as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.

DEVICE

LANTUS® SOLOSTAR® INSULIN PEN

Subjects will use Lantus SoloStar insulin pens when using Lantus as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.

Trial Locations (2)

93105

Sansum Diabetes Research Institute, Santa Barbara

96814

inControl Diabetes Center, Honolulu

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novo Nordisk A/S

INDUSTRY

lead

Sansum Diabetes Research Institute

OTHER